Biohaven Ltd.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-04.
0001935979-26-000045
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-10.
0001935979-26-000066
Item 1A. Risk FactorsUnregistered Sales of Equity Securities Use of ProceedsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 6 previous paragraphs and 4 current paragraphs.
3 unchanged; 0 reworded; 1 added; 3 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (1)
Removed paragraphs (3)
Previous report
Maskbegone Agreement
Previous report
In January 2026, we entered into the Maskbegone Agreement with Maskbegone, pursuant to which we obtained the exclusive rights to develop and commercialize certain products developed under the Maskbegone Agreement related to the use of oxytocin and derivatives of oxytocin in the treatment of tinnitus. As partial consideration under the Maskbegone Agreement, we were obligated to pay an upfront payment of 76,383 common shares valued at approximately $0.9 million, which were issued in the first quarter of 2026.
Previous report
The foregoing issuance and sale of our common shares in connection with the execution of the Maskbegone Agreement have not been registered under the Securities Act or any state securities laws. We have relied on the exemption from the registration requirements of the Securities Act under Section 4(a)(2) thereof, for a transaction by an issuer not involving any public offering.